Clene Inc. (CLNN) - Net Assets
Based on the latest financial reports, Clene Inc. (CLNN) has net assets worth $-17.59 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($18.13 Million) and total liabilities ($35.72 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CLNN asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-17.59 Million |
| % of Total Assets | -97.03% |
| Annual Growth Rate | N/A |
| 5-Year Change | -239.65% |
| 10-Year Change | N/A |
| Growth Volatility | 1349.78 |
Clene Inc. - Net Assets Trend (2018–2025)
This chart illustrates how Clene Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore Clene Inc. asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Clene Inc. (2018–2025)
The table below shows the annual net assets of Clene Inc. from 2018 to 2025. For live valuation and market cap data, see Clene Inc. (CLNN) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-17.59 Million | -98.62% |
| 2024-12-31 | $-8.86 Million | -166.15% |
| 2023-12-31 | $13.39 Million | +313.65% |
| 2022-12-31 | $3.24 Million | -74.30% |
| 2021-12-31 | $12.60 Million | +3594.13% |
| 2020-12-31 | $341.00K | -93.02% |
| 2019-12-31 | $4.89 Million | -2.26% |
| 2018-12-31 | $5.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Clene Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1809136.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | % |
| Other Comprehensive Income | $172.00K | % |
| Other Components | $290.53 Million | % |
| Total Equity | $-17.59 Million | 100.00% |
Clene Inc. Competitors by Market Cap
The table below lists competitors of Clene Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GO Element Co. Ltd.
KQ:311320
|
$72.32 Million |
|
Woosu AMS Co.Ltd
KQ:066590
|
$72.34 Million |
|
Pc Iletisim ve Medya Hizmetleri Sanayi Ticaret AS
IS:PCILT
|
$72.35 Million |
|
Ozsu Balik Uretim A.S.
IS:OZSUB
|
$72.35 Million |
|
Medicalg
WAR:MDG
|
$72.31 Million |
|
Gain Therapeutics Inc
NASDAQ:GANX
|
$72.31 Million |
|
Eaton Vance California MIT
NYSE MKT:CEV
|
$72.31 Million |
|
Humax Holdings Co. Ltd
KQ:028080
|
$72.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Clene Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -8,857,000 to -17,592,000, a change of -8,735,000.
- Net loss of 26,173,000 reduced equity.
- New share issuances of 10,402,000 increased equity.
- Other comprehensive income increased equity by 101,000.
- Other factors increased equity by 6,935,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-26.17 Million | -148.78% |
| Share Issuances | $10.40 Million | +59.13% |
| Other Comprehensive Income | $101.00K | +0.57% |
| Other Changes | $6.93 Million | +39.42% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Clene Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $1.60 | $6.14 | x |
| 2019-12-31 | $1.41 | $6.14 | x |
| 2020-12-31 | $0.10 | $6.14 | x |
| 2021-12-31 | $4.09 | $6.14 | x |
| 2022-12-31 | $0.99 | $6.14 | x |
| 2023-12-31 | $2.55 | $6.14 | x |
| 2024-12-31 | $-1.27 | $6.14 | x |
| 2025-12-31 | $-1.78 | $6.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Clene Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -13086.50%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-920.06%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -5.55% | 0.00% | 0.00x | 9.43x | $-777.31K |
| 2019 | -330.57% | 0.00% | 0.00x | 3.04x | $-16.64 Million |
| 2020 | -5653.08% | -9357.77% | 0.00x | 200.13x | $-19.31 Million |
| 2021 | -77.32% | -1347.16% | 0.01x | 5.01x | $-11.00 Million |
| 2022 | -924.25% | -6325.16% | 0.01x | 13.75x | $-30.24 Million |
| 2023 | -369.71% | -7569.42% | 0.01x | 3.91x | $-50.84 Million |
| 2024 | 0.00% | -11520.47% | 0.01x | 0.00x | $-38.51 Million |
| 2025 | 0.00% | -13086.50% | 0.01x | 0.00x | $-24.41 Million |
Industry Comparison
This section compares Clene Inc.'s net assets metrics with peer companies in the Packaged Foods industry.
Industry Context
- Industry: Packaged Foods
- Average net assets among peers: $1,624,053,735
- Average return on equity (ROE) among peers: -70.68%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Clene Inc. (CLNN) | $-17.59 Million | -5.55% | N/A | $72.32 Million |
| Above Food Ingredients Inc. Common Stock (ABVE) | $-46.26 Million | 0.00% | 0.00x | $27.34 Million |
| Agape ATP Corporation Common Stock (ATPC) | $4.98 Million | -10.43% | 0.03x | $2.34 Million |
| B&G Foods Inc (BGS) | $49.99 Million | 30.34% | 10.00x | $441.46 Million |
| BranchOut Food Inc. Common Stock (BOF) | $2.21 Million | -177.60% | 0.41x | $52.64 Million |
| Bellring Brands LLC (BRBR) | $451.70 Million | 21.28% | 0.24x | $1.82 Billion |
| BRC Inc. (BRCC) | $46.51 Million | -36.00% | 4.07x | $124.97 Million |
| BRF SA ADR (BRFS) | $15.69 Billion | 14.18% | 1.30x | $5.38 Billion |
| Bridgford Foods Corporation (BRID) | $36.90 Million | 17.89% | 0.43x | $68.08 Million |
| Borealis Foods Inc. (BRLS) | $4.64 Million | -566.46% | 12.96x | $32.41 Million |
| Better Choice Company Inc (BTTR) | $-80.79K | 0.00% | 0.00x | $5.13 Million |
About Clene Inc.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral … Read more